Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company’s lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin’s lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts.
Gamma-Delta Frontie | Adicet Bio pioneers engineered gamma-delta T cell therapies, aiming to revolutionize treatment for autoimmune diseases and cancers amid fierce competition |
Financial Tightrope | With $176.3M cash but no revenue, Adicet faces a critical period. Its robust financial health score of 1.57 underscores the urgency of clinical success |
Pipeline Promise | Key trials for lupus nephritis and renal cell carcinoma approach crucial 2025 readouts, with FDA fast-track status highlighting potential market impact |
Market Valuation | Analysts maintain a cautious "Market Perform" outlook. Positive trial results could transform Adicet's $65.5M market cap and industry standing |
Metrics to compare | ACET | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipACETPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.5x | −3.1x | −0.5x | |
PEG Ratio | −0.01 | −0.07 | 0.00 | |
Price/Book | 0.3x | 1.2x | 2.6x | |
Price / LTM Sales | - | 7.2x | 3.3x | |
Upside (Analyst Target) | - | 355.4% | 43.4% | |
Fair Value Upside | Unlock | 17.7% | 7.1% | Unlock |